Ultragenyx ends three GTX-102 trials in Angelman syndrome for lack of efficacyNov 3Trial updateapazunersenUltragenyx Pharmaceutical Inc
Ultragenyx says apazunersen missed both main goals in Phase 3 Angelman syndrome trialSep 2Clinical readoutapazunersenUltragenyx Pharmaceutical Inc
Grace Therapeutics details GTx-104 resubmission plan after CRL, sets cash runway to 2028Aug 13Quarterly updateGrace Therapeutics Inc.
Ultragenyx reports Q2 2026 results, cites two PDUFA dates and Angelman readout aheadAug 4Quarterly updateapazunersenrebisufligene etisparvovec